)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Aspen Pharmacare Holdings (APN) investor relations material
Aspen Pharmacare Holdings H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary4 Sep, 2025
Executive summary
Commercial pharma delivered strong, sustained double-digit CER growth across all segments and regions, especially in Africa, Middle East, and Latin America, with notable momentum in China and successful Latam acquisition.
Faced extreme macroeconomic turbulence, including currency volatility and regulatory changes, requiring a shift in strategy and operational focus.
Loss of a major manufacturing contract and retrospective global tax changes significantly impacted EBITDA, net earnings, and led to increased impairments.
Strategic focus now on sustaining commercial pharma momentum, restructuring manufacturing, and unlocking value from assets.
Operating cash conversion rate reached 147%, a five-year high, supported by improved working capital management.
Financial highlights
Group revenue at ZAR43bn, down 3% reported but up 1% at constant exchange rates; Commercial Pharma revenue up 10% CER, Manufacturing down 19% CER.
Normalized EBITDA at ZAR9.6bn, down 8% year-over-year at CER, mainly due to the contract loss.
Normalized headline earnings per share fell 22% at CER, with higher interest and tax costs.
Gross profit margin improved to 44.1% from 42.6%, driven by higher commercial pharma mix.
Net working capital as % of revenue increased to 47%, above the 45% target, mainly due to contract loss.
Outlook and guidance
Double-digit normalized HEPS growth expected for FY26 at constant currency, supported by improved EBITDA margin.
H1 2026 CER NHEPS to be below H1 2025, but strong double-digit growth expected in H2 2026.
Mid-single digit commercial pharma revenue growth forecast, with higher EBITDA and gross profit margin improvements.
Manufacturing EBITDA targeted to return to positive by FY27, with no GLP-1 income included in current guidance.
CapEx to decline to ZAR3.8bn in FY26, with further reductions planned to align with depreciation by FY27/28; leverage ratio projected to fall below 3x.
GLP-1 generic market entry strategy details
FDF sterile turnaround plan & divestment options?
Capital allocation to reduce debt below 3x?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aspen Pharmacare Holdings earnings date
H1 20263 Mar, 2026
Next Aspen Pharmacare Holdings earnings date
H1 20263 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Aspen Pharmacare Holdings Limited (Aspen) is a global pharmaceutical company headquartered in Durban, South Africa. Established in 1997, Aspen has grown to become a leading provider of generic and specialty pharmaceuticals, focusing on a range of therapeutic categories including thrombosis, anaesthetics, and high potency and cytotoxic treatments. The company's product portfolio encompasses a variety of dosage forms such as oral solid dose, semi-solids, liquids, steriles, biologicals, personal care products, and active pharmaceutical ingredients (APIs). Aspen's shares are listed on the Johannesburg Stock Exchange (JSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage